Riluzole improved the cognitive impairment induced by lipopolysaccharide in mice with SLC1A1/EAAT3 (solute carrier family 1 member 1/Excitatory amino acid transporter 3) expression knocked down, suggesting that it may normalise the expression of EAAT3 [61, 62] and glucose metabolism [63]. The gene discussed is SLC1A1; the disease is Cognitive impairment.